Abstract: Objective To evaluate the clinical value of CT-guided radioactive 125I seed implantation brachytherapy for refractory metastatic liver cancer.
Methods Forty refractory metastatic liver cancer patients with 94 measurable metastatic foci were treated under the CT-guided with the 125I radioactivity seed interstitial brachytherapy from January 2010 to January 2012. The clinical effects， postoperative complications and adverse reactions were evaluated. Results After operation for 6 months， of all the 94 measurable metastatic foci， 32 foci got complete response （CR）， partial response （CR） was observed in 48 foci， stable disease（SD） in 9 foci and progressive disease （PD） in 5 foci. The response rate （RR） was 85.1％. The follow-up ranged from 4 to 31 months （average 13 months）. At the end of the followup period， 1-year survival rate was 75.0％. No serious operative or postoperative complications and grade 3-4 adverse effects occurred. Conclusion CT-guided 125I seed implantation brachytherapy showed good clinical effects but fewer side effects. It can be used as a new treatment option for patients with refractory metastatic liver cancer.